No profile data available.
Johnson & Johnson (JNJ) is a healthcare company in the multi-therapeutic drug manufacturing industry, based in New Brunswick, United States, with about 138,200 full-time employees.
It reported revenue of $94.19 billion for fiscal year 2025, up 6.0% from fiscal year 2024, and net income of $26.80 billion. In Q2 2026 (the quarter ended June 30, 2026) revenue was $25.31 billion, up 6.6% from a year before. Its largest business segment, Innovative Medicine, brought in 64% of segment revenue in fiscal year 2025; United States was the largest region with 57%. Its market capitalization was $630.04 billion as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech.
Johnson & Johnson reported $94.19 billion in revenue for fiscal year 2025, up 6.0% from $88.82 billion in fiscal year 2024. In Q2 2026 revenue was $25.31 billion.
Innovative Medicine, with $60.40 billion or 64% of segment revenue in fiscal year 2025. Next: Medtech (36%).
United States: 57% of revenue by region in fiscal year 2025, followed by Europe (23%).
$630.04 billion as of October 9, 2026.
Listed companies of a similar size in the same industry (multi-therapeutic drug manufacturing) include AbbVie Inc. (ABBV), Novartis AG (NVS), AstraZeneca PLC (AZN), Amgen Inc. (AMGN).